Cholangiocarcinoma
Drug research and approvals for cholangiocarcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 214 studies of cholangiocarcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 14 drug trials for it since 2013, FDA has 5 approved and 26 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 214
- Trials authorized in Canada: 14
- FDA orphan approvals: 5
- EU medicines: 2
Recruiting Now
Newest start dates first, of 214 recruiting on ClinicalTrials.gov ↗- SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METNCT07873450 · Phase 1 / Phase 2 · Full-Life Technologies UK Limited · starts Dec 1, 2026
- TCR1188-ABC Cells in KRAS-mutated CancersNCT07594067 · Phase 1 · University of Pennsylvania · starts Dec 1, 2026
- Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic CholangiocarcinomaNCT07766187 · Phase 2 · University of Wisconsin, Madison · starts Nov 1, 2026
- Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaNCT07780838 · Phase 2 · Ohio State University Comprehensive Cancer Center · starts Nov 1, 2026
- [18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to…NCT07673341 · Phase 2 · University of Washington · starts Oct 8, 2026
- EUS Examination Using EndoSound Vision System vs. Standard EchoendoscopeNCT06340620 · Not applicable · Orlando Health, Inc. · starts Oct 1, 2026
- Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct TumorsNCT07726446 · Phase 2 · Tianjin Medical University Cancer Institute and Hospital · starts Oct 1, 2026
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic…NCT07847710 · Phase 2 · The First Affiliated Hospital with Nanjing Medical University · starts Sep 30, 2026
- A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic CholangiocarcinomaNCT07522476 · Phase 2 · Virogin Biotech Ltd. · starts Aug 25, 2026
- Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive CholangiocarcinomaNCT07786766 · Phase 2 · Haitao Zhao, MD · starts Aug 20, 2026
Trials Authorized in Canada
The 10 newest of 14; search them all in Canada trials| Jun 5, 2025 | A phase 1b/2, safety lead-in and dose-expansion, open label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib…IVOSIDENIB / DURVALUMAB / CISPLATIN / GEMCITABINE | Servier | Ongoing |
| May 8, 2025 | Perioperative therapy with gemcitabine/cisplatin/nab-paclitaxel and rilvegostomig (azd2936) for patients with resectable intrahepatic cholangiocarcinoma (icca)…GEMCITABINE / CISPLATIN / ABRAXANE / RILVEGOSTOMIG | UNIVERSITY HEALTH NETWORK | Ongoing |
| Feb 27, 2025 | Phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma with fgfr2 fusions or rearrangementsFUTIBATINIB (TAS-120) | Taiho Oncology | Ongoing |
| Dec 23, 2024 | A phase 1/2 study of a selective fgfr2/3 inhibitor, cgt4859, in patients with cholangiocarcinoma and other advanced solid tumors harboring fgfr2 and/or fgfr3…CGT4859 | COGENT BIOSCIENCES, INC. | Closed |
| Jul 20, 2023 | A phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating lsta1 when added to standard of care (soc) versus standard of care…CERTEPETIDE (LSTA1) | LISATA THERAPEUTICS, INC. | Closed |
| Jun 22, 2023 | A first-in-human study of highly selective fgfr2 inhibitor, rly-4008, in patients with intrahepatic cholangiocarcinoma (icc) and other advanced solid tumorsRLY-4008 | RELAY THERAPEUTICS, INC. | Closed |
| Apr 14, 2022 | A study to evaluate the efficacy of propranolol in boosting immunotherapy in hepatocellular carcinoma, cholangiocarcinoma and pancreatic adenocarcinoma…TREMELIMUMAB / DURVALUMAB / PROPRANOLOL | CROSS CANCER INSTITUTE - CANCER CARE ALBERTA | Ongoing |
| Oct 22, 2020 | A phase 3, open-label, randomized study of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of patients with advanced…FUTIBATINIB (TAS-120) / GEMCITABINE / CISPLATIN | Taiho Oncology | Pending |
| Aug 16, 2019 | A phase 3 multicenter, open-label, randomized, controlled study of oral infigratinib versus gemcitabine with cisplatin in subjects with advanced/metastatic or…INFIGRATINIB (BGJ398)/ GEMCITABINE/ CISPLATIN | QED THERAPEUTICS, INC. | Closed |
| Jun 12, 2019 | A multi-centre, open-label phase 2 study of trifluridine/tipiracil in previously treated cholangiocarcinoma (the mocha trial)TRIFLURIDINE-TIPIRACIL | SUNNYBROOK RESEARCH INSTITUTE | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 31| Sep 23, 2026 | Lyrfigtutreatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth… | Elevar Therapeutics, Inc. | Approved |
| May 8, 2026 | Bizengritreatment of adults with advanced unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease… | Partner Therapeutics, Inc. | Approved |
| Sep 30, 2022 | LytgobiTreatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring… | Taiho Oncology, Inc. | Approved |
| Aug 25, 2021 | TibsovoTreatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1… | Servier Pharmaceuticals LLC | Approved |
| Apr 17, 2020 | PEMAZYREPEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma… | Incyte Corporation | Approved |
| Mar 8, 2026 | antibody-drug conjugate (ADC) composed of the humanized…treatment of cholangiocarcinoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd | Designated |
| Nov 14, 2025 | antibody-drug conjugate (ADC) consisting of a humanized…treatment of cholangiocarcinoma | OBI Pharma USA Inc. | Designated |
| Dec 5, 2024 | butaselentreatment of cholangiocarcinoma | Shanghai Yuanxi Medicine Corp. | Designated |
| Sep 17, 2024 | Chimeric virus with a double-stranded DNA genome comprised…treatment of cholangiocarcinoma | Imugene Limited | Designated |
| Aug 21, 2024 | N-(4-(4-Amino-7-cyano-1-methyl-3-(4-((4-methylpyrimidin-2-yl…treatment of cholangiocarcinoma (CCA) | 3H (Suzhou) Pharmaceuticals Co., Ltd. | Designated |
| Aug 5, 2024 | certepetidetreatment of cholangiocarcinoma | Lisata Therapeutics, Inc | Designated |
| Aug 16, 2023 | N-[5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluor…Treatment of cholangiocarcinoma | Nuvectis Pharma, Inc. | Designated |
| Jan 23, 2023 | recombinant human IL12/15-PDL1B HSV-1 oncolytic virus…Treatment of cholangiocarcinoma | Virogin Biotech Canada Ltd | Designated |
| Oct 19, 2022 | a humanized immunoglobulin IgG1 antibody with a kappa light…Treatment of Cholangiocarcinoma | ZielBio Incorporated | Designated |
| Oct 11, 2022 | N-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-b]py…Treatment of cholangiocarcinoma | 3D Medicines (Beijing) Co., Ltd | Designated |
Medicines Authorised in the EU
Newest first| Jul 4, 2023 | Lytgobifutibatinib | Taiho Pharma Netherlands B.V. | EMA ↗ |
| Mar 26, 2021 | Pemazyrepemigatinib · orphan | Incyte Biosciences Distribution B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA